DIAGNOS INC (ADK.CA) Stock Fundamental Analysis
TSX-V:ADK - TSX Venture Exchange - CA2524423068 - Common Stock - Currency: CAD
Overall ADK gets a fundamental rating of 1 out of 10. We evaluated ADK against 8 industry peers in the Health Care Technology industry. ADK has a bad profitability rating. Also its financial health evaluation is rather negative. ADK has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ADK had negative earnings in the past year.
In the past year ADK has reported a negative cash flow from operations.
In the past 5 years ADK always reported negative net income.
ADK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ADK has a worse Return On Assets (-117.88%) than 75.00% of its industry peers.
The Return On Equity of ADK (-1838.87%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.88% | ||
| ROE | -1838.87% | ||
| ROIC | N/A |
ROA(3y)-296.48%
ROA(5y)-232.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ADK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADK has more shares outstanding
The number of shares outstanding for ADK has been increased compared to 5 years ago.
The debt/assets ratio for ADK has been reduced compared to a year ago.
2.2 Solvency
ADK has an Altman-Z score of -16.90. This is a bad value and indicates that ADK is not financially healthy and even has some risk of bankruptcy.
ADK's Altman-Z score of -16.90 is on the low side compared to the rest of the industry. ADK is outperformed by 62.50% of its industry peers.
ADK has a Debt/Equity ratio of 1.23. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.23, ADK is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.9 |
ROIC/WACCN/A
WACC9.35%
2.3 Liquidity
ADK has a Current Ratio of 1.11. This is a normal value and indicates that ADK is financially healthy and should not expect problems in meeting its short term obligations.
ADK has a Current ratio of 1.11. This is in the better half of the industry: ADK outperforms 62.50% of its industry peers.
ADK has a Quick Ratio of 1.11. This is a normal value and indicates that ADK is financially healthy and should not expect problems in meeting its short term obligations.
ADK has a better Quick ratio (1.11) than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.11 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
The earnings per share for ADK have decreased strongly by -11.89% in the last year.
ADK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -38.98%.
ADK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.72% yearly.
EPS 1Y (TTM)-11.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-38.98%
Revenue growth 3Y-38.15%
Revenue growth 5Y-20.72%
Sales Q2Q%-56.19%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ADK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ADK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:ADK (7/25/2025, 7:00:00 PM)
0.205
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners4.91%
Ins Owner ChangeN/A
Market Cap20.88M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-74.35%
Min Revenue beat(2)-85.82%
Max Revenue beat(2)-62.88%
Revenue beat(4)0
Avg Revenue beat(4)-65.18%
Min Revenue beat(4)-85.82%
Max Revenue beat(4)-47.62%
Revenue beat(8)0
Avg Revenue beat(8)-58.09%
Revenue beat(12)0
Avg Revenue beat(12)-50.51%
Revenue beat(16)2
Avg Revenue beat(16)-40.7%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 201.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 89.58 | ||
| P/tB | 89.58 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.88% | ||
| ROE | -1838.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-296.48%
ROA(5y)-232.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.67% | ||
| Cap/Sales | 13.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.11 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | -16.9 |
F-Score4
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)14.45%
Cap/Depr(5y)23.63%
Cap/Sales(3y)8.19%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-38.98%
Revenue growth 3Y-38.15%
Revenue growth 5Y-20.72%
Sales Q2Q%-56.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.39%
OCF growth 3YN/A
OCF growth 5YN/A